Literature DB >> 25859124

Pharmacotherapy of neuropsychiatric symptoms of dementia.

David A Casey.   

Abstract

Approximately 5 million Americans have dementia, and many receive psychiatric medications. Management of such patients is complex and controversial, and it has become apparent that all potential pharmacological therapies present risks.

Entities:  

Year:  2015        PMID： 25859124      PMCID： PMC4378522     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  29 in total

1.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.

Authors:  I R Katz; D V Jeste; J E Mintzer; C Clyde; J Napolitano; M Brecher
Journal:  J Clin Psychiatry       Date:  1999-02       Impact factor: 4.384

2.  Antidepressants for agitation and psychosis in patients with dementia.

Authors:  Quynh Bui
Journal:  Am Fam Physician       Date:  2012-01-01       Impact factor: 3.292

3.  Neuropsychiatric symptoms in Alzheimer's disease.

Authors:  Constantine G Lyketsos; Maria C Carrillo; J Michael Ryan; Ara S Khachaturian; Paula Trzepacz; Joan Amatniek; Jesse Cedarbaum; Robert Brashear; David S Miller
Journal:  Alzheimers Dement       Date:  2011-09       Impact factor: 21.566

Review 4.  Evidence-based practices in geriatric mental health care.

Authors:  Stephen J Bartels; Aricca R Dums; Thomas E Oxman; Lon S Schneider; Patricia A Areán; George S Alexopoulos; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2002-11       Impact factor: 3.084

5.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.

Authors:  Lon S Schneider; Karen Dagerman; Philip S Insel
Journal:  Am J Geriatr Psychiatry       Date:  2006-03       Impact factor: 4.105

6.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications.

Authors:  Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

7.  2014 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2014-03       Impact factor: 21.566

8.  Relapse risk after discontinuation of risperidone in Alzheimer's disease.

Authors:  D P Devanand; Jacobo Mintzer; Susan K Schultz; Howard F Andrews; David L Sultzer; Danilo de la Pena; Sanjay Gupta; Sylvia Colon; Corbett Schimming; Gregory H Pelton; Bruce Levin
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

9.  Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial.

Authors:  Bettina S Husebo; Clive Ballard; Reidun Sandvik; Odd Bjarte Nilsen; Dag Aarsland
Journal:  BMJ       Date:  2011-07-15

10.  The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study.

Authors:  Sibel Cakir; Isin Baral Kulaksizoglu
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.